Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT00863746
Activo, no recluta
Fase 3
ClinicalTrials.gov
Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors
INTERVENTIONAL
Inicio: 6 de feb de 2020
ID: NCT04154956
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
INTERVENTIONAL
Inicio: 13 de dic de 2022
ID: NCT05668988
Desconocido
Fase 3
ClinicalTrials.gov
Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19)
INTERVENTIONAL
Inicio: 1 de jun de 2021
ID: NCT04913779
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
INTERVENTIONAL
Inicio: 20 de feb de 2024
ID: NCT06117774
Completado
ClinicalTrials.gov
Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2
OBSERVATIONAL
Inicio: 10 de mar de 2020
ID: NCT04174313
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de mar de 2002
ID: NCT00034268
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
INTERVENTIONAL
Inicio: 24 de abr de 2025
ID: NCT06875310
Completado
Fase 3
ClinicalTrials.gov
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
INTERVENTIONAL
Inicio: 23 de dic de 2009
ID: NCT01000025
Terminado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
INTERVENTIONAL
Inicio: 18 de mar de 2021
ID: NCT04705597
Desconocido
Fase 4
ClinicalTrials.gov
Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)
INTERVENTIONAL
Inicio: 1 de jun de 2020
ID: NCT04530578
Reclutando
ClinicalTrials.gov
Medtronic Product Surveillance Registry
OBSERVATIONAL
Inicio: 1 de ene de 2012
ID: NCT01524276
Completado
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy
INTERVENTIONAL
Inicio: 25 de jun de 2011
ID: NCT01351415
Completado
Fase 3
ClinicalTrials.gov
A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00633893
Terminado
Fase 1
ClinicalTrials.gov
A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection
INTERVENTIONAL
Inicio: 4 de dic de 2015
ID: NCT02593851
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00457002
Completado
ClinicalTrials.gov
A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.
OBSERVATIONAL
Inicio: 25 de jul de 2016
ID: NCT02760329
Reclutando
Fase 1
ClinicalTrials.gov
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
INTERVENTIONAL
Inicio: 17 de sept de 2024
ID: NCT06333951
Desconocido
ClinicalTrials.gov
Recruitment Assessment in Patients With Acute Respiratory Distress Syndrome and Covid-19
OBSERVATIONAL
Inicio: 7 de mar de 2022
ID: NCT05248243
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 14 de feb de 2023
ID: NCT05722015
Anterior
1
...
38
39
40
...
434
Siguiente
Filtros